A retrospective study of comparison between Diflunisal and Tafamidis used for the treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM)
Latest Information Update: 03 Jul 2021
At a glance
- Drugs Tafamidis meglumine (Primary) ; Diflunisal
- Indications Cardiomyopathies; Transthyretin-related hereditary amyloidosis
- Focus Therapeutic Use
- 03 Jul 2021 New trial record
- 17 May 2021 Results presented at the 70th Annual Scientific Session of the American College of Cardiology